Ferriprox(deferiprone)
Ferriprox (deferiprone) is a small molecule pharmaceutical. Deferiprone was first approved as Ferriprox on 1999-08-25. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Ferriprox (generic drugs available since 2019-02-08)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
deferiprone | ANDA | 2022-08-12 |
ferriprox | New Drug Application | 2021-11-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
iron overload | — | D019190 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
DEFERIPRONE, FERRIPROX, CHIESI | |||
2028-04-30 | ODE-417, ODE-418, ODE-419, ODE-420, ODE-421 | ||
2024-04-30 | I-859 |
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Iron overload | D019190 | — | 5 | 2 | 4 | 3 | 14 | ||
Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 4 | 3 | 4 | 3 | 11 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | 1 | 2 | — | 4 |
Hemosiderosis | D006486 | — | 1 | 1 | 1 | — | 2 | ||
Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Hepatic insufficiency | D048550 | — | — | — | 1 | — | 1 | ||
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 4 | 1 | — | 1 | 5 |
Pantothenate kinase-associated neurodegeneration | D006211 | G23.0 | — | — | 2 | — | 1 | 3 | |
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 2 | 1 | — | 1 | 3 |
Hemochromatosis | D006432 | EFO_1000642 | E83.11 | — | 1 | 1 | — | — | 2 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | — | — | 1 |
Peptic ulcer | D010437 | HP_0004398 | K27 | — | 1 | 1 | — | — | 1 |
Iron metabolism disorders | D019189 | E83.1 | — | 1 | 1 | — | — | 1 | |
Sensorineural hearing loss | D006319 | HP_0000407 | H90.5 | — | 1 | 1 | — | — | 1 |
Optic atrophy | D009896 | H47.2 | — | 1 | 1 | — | — | 1 | |
Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thalassemia | D013789 | EFO_1001996 | D56 | 1 | 1 | — | — | 2 | 3 |
Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | — | 2 | |
Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | 1 | 2 | — | — | — | 2 |
Dementia | D003704 | F03 | 1 | 1 | — | — | — | 1 | |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | D46 | — | 1 | — | — | — | 1 | |
Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 1 | — | — | — | 1 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
Asymptomatic infections | D058345 | 1 | — | — | — | — | 1 | ||
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DEFERIPRONE |
INN | deferiprone |
Description | Deferiprone is a member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. It has a role as an iron chelator and a protective agent. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1c(O)c(=O)ccn1C |
Identifiers
PDB | — |
CAS-ID | 30652-11-0 |
RxCUI | 11645 |
ChEMBL ID | CHEMBL70927 |
ChEBI ID | 68554 |
PubChem CID | 2972 |
DrugBank | DB08826 |
UNII ID | 2BTY8KH53L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,527 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferiprone, Ferriprox
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
11,467 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more